Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Review

(4298) Views  (2081) Full article downloads

Authors: Michael A Via, Himani Chandra, Takako Araki, et al

Published Date March 2010 Volume 2010:3 Pages 43 - 48

DOI: http://dx.doi.org/10.2147/DMSO.S9575

Michael A Via¹, Himani Chandra², Takako Araki¹, Matthew V Potenza³, Maria Skamagas⁴

¹Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; ²Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, James J Peters VA Medical Center, New York, NY, USA; ³Diabetes and Endocrinology, West Nyack, New York, NY, USA; ⁴Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, USA

Abstract: Type 2 diabetes mellitus (T2DM) continues to rise in prevalence in the United States and worldwide. Despite advances in medical treatments for T2DM, many patients remain uncontrolled. By targeting centrally mediated pathways of glucose metabolism, bromocriptine represents a novel therapeutic option in T2DM. Several small clinical trials demonstrate improvements in insulin resistance and glycemic control. After the submission of data from four recent, large clinical trials, the US Food and Drug Administration has approved the use of bromocriptine in T2DM. We review the available data from these four trials and other published studies. Bromocriptine is a promising therapy for diabetes patients and demonstrates modest improvements in glycemic control.

Keywords: bromocriptine, dopamine agonists, diabetes, glycemic control

Readers of this article also read: